PuSH - Publication Server of Helmholtz Zentrum München: Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Bette, S.* ; Barz, M.* ; Wiestler, B.* ; Huber, T.* ; Gerhardt, J.* ; Buchmann, N.* ; Combs, S.E. ; Schmidt-Graf, F.* ; Delbridge, C.* ; Zimmer, C.* ; Kirschke, J.S.* ; Meyer, B.* ; Ryang, Y.M.* ; Ringel, F.* ; Gempt, J.*

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

Ann. Surg. Oncol. 25, 1-7 (2017)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy. The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy. Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm(3)). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen. Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001). In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Newly-diagnosed Glioblastoma; Adjuvant Temozolomide; Molecular Markers; Ncic Trial; Phase-iii; Survival; Extent; Surgery; Multiforme; Eortc

ISSN (print) / ISBN 1068-9265

e-ISSN 1534-4681

Journal Annals of Surgical Oncology

Quellenangaben Volume: 25, Issue: 2, Pages: 1-7

Publisher Springer

Publishing Place New York

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Radiation Medicine (IRM)